Cargando…
Current Molecular Therapeutic Agents and Drug Candidates for Mycobacterium abscessus
Mycobacterium abscessus has been recognised as a dreadful respiratory pathogen among the non-tuberculous mycobacteria (NTM) because of misdiagnosis, prolonged therapy with poor treatment outcomes and a high cost. This pathogen also shows extremely high antimicrobial resistance against current antibi...
Autores principales: | Quang, Nguyen Thanh, Jang, Jichan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435730/ https://www.ncbi.nlm.nih.gov/pubmed/34526902 http://dx.doi.org/10.3389/fphar.2021.724725 |
Ejemplares similares
-
Omadacycline Potentiates Clarithromycin Activity Against Mycobacterium abscessus
por: Bich Hanh, Bui Thi, et al.
Publicado: (2021) -
Thiostrepton: A Novel Therapeutic Drug Candidate for Mycobacterium abscessus Infection
por: Kim, Tae Ho, et al.
Publicado: (2019) -
CRISPR Interference-Based Inhibition of MAB_0055c Expression Alters Drug Sensitivity in Mycobacterium abscessus
por: Nguyen, Thanh Quang, et al.
Publicado: (2023) -
Rifamycin O, An Alternative Anti-Mycobacterium abscessus Agent
por: Hanh, Bui Thi Bich, et al.
Publicado: (2020) -
Pathogen Box screening for hit identification against Mycobacterium abscessus
por: Jeong, Jinsun, et al.
Publicado: (2018)